Georgia Governor Brian Kemp has signed Senate Bill 220 (SB 220), officially known as the “Putting Georgia’s Patients First Act,” into law, expanding medical cannabis access and the types of products available to registered patients. The legislation, signed on Tuesday, introduces several changes to the state’s medical cannabis program, affecting product potency, permissible consumption methods, and qualifying conditions.
The new law replaces previous statutory references to “low THC oil” with the broader term “medical cannabis.” It also modifies the regulatory framework for product manufacturing and patient possession, as reported by NORML.
Key Provisions of Senate Bill 220
SB 220 enacts several changes to Georgia’s medical cannabis regulations:
- THC Cap Removal: The previous 5 percent THC cap on medical cannabis products has been removed. Patients are now permitted to possess products containing a cumulative total of 12,000 milligrams or less of THC, as detailed by CBS News Atlanta.
- Expanded Product Forms: The law allows for the sale of vape products to patients over 21 years of age. Previously, dispensaries were limited to offering cannabis products in pill, tincture, and some edible forms. Smoking botanical cannabis (flower or bud) remains prohibited.
- New Qualifying Conditions: The list of qualifying medical conditions has been expanded to include inflammatory bowel disease and lupus. Requirements for patients with conditions such as multiple sclerosis and Parkinson’s disease have also been eased, according to 13WMAZ.
- Packaging Requirements: All medical cannabis products must be packaged in a pharmaceutical container that specifies the amount of THC contained within.
- Public Use Prohibition: The public use of medical cannabis products remains prohibited under the new law.
Industry and Patient Impact
Industry stakeholders anticipate that the expanded medical cannabis access will provide greater relief for patients. A cannabis dispensary general manager stated that the legislation addresses a long-standing need within the medical cannabis community for enhanced treatment options. Dispensaries are expected to offer various lab-tested, Georgia-grown, and manufactured products, including vape products, starting July 1.
A general manager at a medical cannabis production facility expressed optimism that the law will encourage more individuals to seek cannabis for medicinal use. The 12,000-milligram THC limit is noted to provide clarity for patients to find suitable products.
A patient highlighted the importance of affordability as Georgia’s medical cannabis program expands.
Governor Kemp’s Statement
In his signing statement, Governor Kemp acknowledged public concerns regarding the expansion of medical cannabis. He affirmed his reservations about the legalization of recreational cannabis, stating, “I do not believe that a well-implemented medical cannabis program must inevitably lead to the legalization of recreational use in Georgia.” However, he also recognized that for some patients, medical cannabis offers significant relief for symptoms that might otherwise be untreated or managed with more harmful substances like opioids.
Background and Resources
Georgia initially approved legislation in 2015 to legalize the possession of non-herbal, low-THC oils for authorized patients. However, the state did not license dispensaries to provide these products until 2023. Currently, over 33,000 patients are enrolled in Georgia’s medical cannabis access program. The full text of Senate Bill 220 is available from the Georgia General Assembly.
Individuals seeking more information about registering for a medical cannabis card can visit the Georgia Department of Public Health or the Georgia Medical Cannabis Commission websites.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
